GleamWall
中文EN

INTS INTENSITY THERAPEUTICS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1567264 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-2.6%
TTM EPS YoY90.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-161.8%
ROA-121.1%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets25.6%
Debt / equity0.00x
Current ratio3.68x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.75x
Accruals ratio-29.9%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$2.43M$1.83M$1.20M$1.50M$1.55M$1.54M$2.19M$1.97M
SG&A expense$1.19M$1.25M$1.33M$1.64M$1.18M$1.16M$1.21M$1.24M
Operating income-$3.62M-$3.08M-$2.53M-$3.14M-$2.73M-$2.71M-$3.39M-$3.20M
Interest expense———————$0
Net income-$3.54M-$3.01M-$2.43M-$3.05M-$2.67M-$2.54M-$3.35M-$3.18M
EPS (basic)-1.09-1.11-0.96—-1.55-3.36-5.51—
EPS (diluted)-1.09-1.11-0.96—-1.55-3.36-5.51—
Weighted avg. shares (diluted)3.26M2.71M2.53M—1.72M754,725606,928—
Balance sheet
Cash & equivalents$8.49M$9.53M$10.24M$11.92M$7.07M$2.22M$929,000$2.59M
Receivables$41,278———————
Current assets$9.50M$11.23M$10.91M$12.71M$8.19M$3.04M$1.65M$3.36M
Total assets$10.29M$11.52M$12.29M$14.10M$9.59M$4.44M$3.06M$4.78M
Current liabilities$2.58M$2.25M$2.24M$2.15M$2.28M$2.16M$2.63M$1.75M
Total liabilities$2.63M$2.31M$2.31M$2.23M$2.36M$2.26M$2.73M$1.86M
Shareholders' equity$7.65M$9.21M$9.98M$11.88M$7.22M$2.18M$334,000$2.92M
Shares outstanding3.30M2.95M2.54M2.52M49.07M26.17M15.26M604,915
Cash flow statement
Operating cash flow-$2.50M-$2.34M-$1.83M-$2.40M-$2.39M-$2.46M-$1.99M-$2.67M
Investing cash flow———$0$0$0$0$0
Financing cash flow$1.47M$1.62M$150,000$7.25M$7.24M$3.74M$328,000$2.48M
Stock-based compensation$517,000$387,000$387,000$450,000$471,000$644,000$435,000$844,000

Free plan shows the latest 8 periods; Pro shows all 18 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.